Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

NCT01274338 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1673

Enrollment

NIH

Sponsor class

Conditions

Melanoma of Unknown Primary
Recurrent Melanoma
Stage IIIB Cutaneous Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions

BIOLOGICAL: Ipilimumab
OTHER: Quality-of-Life Assessment
BIOLOGICAL: Recombinant Interferon Alfa-2b

Sponsor

National Cancer Institute (NCI)